Submission based on overwhelmingly positive top-line results from GENESIS Phase 3 study
Stem cell mobilization for bone marrow transplantation estimated to be > $360 million market in the U.S. ( > $500 million globally), with consistent growth
Monday, September 12, 2022
BioLineRx: New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.